Related Experiment Videos

[Treatment of exacerbations of chronic obstructive pulmonary disease with pristinamycin]

P Léophonte1, C Chidiac, H B Drugeon

  • 1Service de Pneumologie, Hôpital Larrey, Cliniques des voies respiratoires, Toulouse, France. leophonte.p@chu-toulouse.fr

Revue Des Maladies Respiratoires
|June 24, 2004
PubMed
Abstract

Insights

Pristinamycin offers a short, 4-day treatment for acute exacerbations of chronic obstructive bronchitis (AECB), proving as effective and safe as the standard 8-day co-amoxiclav regimen.

Area of Science:

  • Respiratory Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Pristinamycin is a bactericidal antibiotic effective against key respiratory pathogens.
  • Its efficacy in short-course therapy for acute exacerbations of chronic obstructive bronchitis (AECB) was previously unevaluated.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a short-course pristinamycin regimen for AECB.

Main Methods:

  • A randomized trial compared 4-day pristinamycin (3g daily) with 8-day co-amoxiclav (2g daily) in 476 AECB patients.
  • Follow-up duration was six months.

Main Results:

  • Clinical success rates at 21 days were similar: 87.2% for pristinamycin vs. 87.9% for co-amoxiclav.
  • Bacteriological response was favorable in 84.6% of pristinamycin patients versus 78.2% of co-amoxiclav patients.
  • Relapse rates and treatment-related side effects were comparable between groups.

Conclusions:

  • A 4-day course of pristinamycin is as effective and well-tolerated as an 8-day course of co-amoxiclav for treating AECB.
  • Pristinamycin presents a viable alternative for short-course AECB treatment.

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...